Effect of aprotinin (trasylol) on the inflammatory and thrombotic complications of conventional cardiopulmonary bypass surgery.
Before the discovery of its hemostatic properties, aprotinin was thought of as a potential anti-inflammatory agent. Its clinical introduction in 1987 to prevent blood loss during cardiac surgery [Royston 1987, van Oeveren 1987] led to its anti-inflammatory benefits being largely overlooked in favor of a vigorous debate centering on whether aprotinin may be pro-thrombotic when given to patients. In this article, we summarize evidence for the anti-inflammatory activity of aprotinin and discuss our recent contributions in this area. We also summarize the state of the thrombosis debate and discuss our recent evidence from purified platelets which shows that aprotinin is simultaneously hemostatic yet anti-thrombotic.
Landis
R C
RC
British Heart Foundation Unit of Cardiovascular Medicine, Imperial College School of Medicine, Hammersmith Hospital, Lonson W12 0NN, UK. rlandis@ic.ac.uk
Asimakopoulos
G
G
Poullis
M
M
Thompson
R
R
Nourshargh
S
S
Haskard
D O
DO
Taylor
K M
KM
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D006490:Hemostatics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D020766:Intracranial Embolism / Q000209:etiology / Q000517:prevention & control*; D007962:Leukocytes / Q000187:drug effects; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000517:prevention & control*
D006490:Hemostatics; D007611:Aprotinin